Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial

BACKGROUND: Simvastatin is a promising new drug for the treatment of endometriosis. It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and monocyte chemoattractant protein-1 (MCP-1). This study investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Waiyaput, Wanwisa, Pumipichet, Somphoch, Weerakiet, Sawaek, Rattanasiri, Sasivimol, Sophonsritsuk, Areepan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615793/
https://www.ncbi.nlm.nih.gov/pubmed/28950844
http://dx.doi.org/10.1186/s12905-017-0446-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615793/
https://www.ncbi.nlm.nih.gov/pubmed/28950844
http://dx.doi.org/10.1186/s12905-017-0446-3

Ejemplares similares